Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis.
Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis.
复制标题
DOI：
10.1158/1055-9965.epi-10-0180
复制
发表时间：
2010-06
期刊：
影响因子：
--
通讯作者：
Martin RM
中科院分区：
文献类型：
--
作者：
Collin SM;Metcalfe C;Refsum H;Lewis SJ;Zuccolo L;Smith GD;Chen L;Harris R;Davis M;Marsden G;Johnston C;Lane JA;Ebbing M;Bønaa KH;Nygård O;Ueland PM;Grau MV;Baron JA;Donovan JL;Neal DE;Hamdy FC;Smith AD;Martin RM
叶酸代谢紊乱与某些癌症的风险增加有关。我们的目的是确定血液中叶酸、维生素B12和相关代谢物的水平是否与前列腺癌风险相关。匹配的病例对照研究嵌套在英国基于人群的ProtecT研究中，在50-69岁的男性中进行PSA检测的前列腺癌。在1，461例病例和1，507例对照组中测定了叶酸、B12（钴胺素）、全结合咕啉、全转钴胺素和总转钴胺素以及总同型半胱氨酸（tHcy）的血浆浓度。ProtecT研究对叶酸、B12和tHcy与前列腺癌风险相关性的估计被纳入基于系统综述的荟萃分析。在ProtecT研究中，B12和全结合咕啉浓度增加与前列腺癌风险呈正相关，（B12比值比（OR）的最高与最低四分位数=1.17（95% CI 0.95-1.43），趋势P =0.06;全结合咕啉的最高与最低四分位数OR=1.27（1.04-1.56），趋势P =0.01）;叶酸、全转钴胺素和tHcy与前列腺癌风险无关。在荟萃分析中，循环B12水平与前列腺癌风险增加相关B12每增加100 pmol/L，合并OR=1.10（1.01-1.19），P=0.002;叶酸与前列腺癌相关的合并OR为正（OR=1.11（0.96-1.28）/10 nmol/L，P=0.2），如果排除ProtecT（唯一的病例对照研究），则具有传统统计学意义（OR=1.18（1.00-1.40）/10 nmol/L，P=0.02）。维生素B12和（在队列研究中）叶酸与前列腺癌风险增加有关。鉴于目前对强制性强化的争议，需要进一步的研究来确定这些是否是因果关系。
Disturbed folate metabolism is associated with an increased risk of some cancers. Our objective was to determine whether blood levels of folate, vitamin B12 and related metabolites were associated with prostate cancer risk. Matched case-control study nested within the UK population-based ProtecT study of PSA-detected prostate cancer in men aged 50–69 years. Plasma concentrations of folate, B12 (cobalamin), holo-haptocorrin, holo- and total-transcobalamin, and total homocysteine (tHcy) were measured in 1,461 cases and 1,507 controls. ProtecT study estimates for associations of folate, B12, and tHcy with prostate cancer risk were included in a meta-analysis, based on a systematic review. In the ProtecT study, increased B12 and holo-haptocorrin concentrations showed positive associations with prostate cancer risk (highest vs lowest quartile of B12 odds ratio (OR)=1.17 (95% CI 0.95–1.43), P-for-trend=0.06; highest vs lowest quartile of holo-haptocorrin OR=1.27 (1.04–1.56), P-for-trend=0.01); folate, holo-transcobalamin and tHcy were not associated with prostate cancer risk. In the meta-analysis, circulating B12 levels were associated with an increased prostate cancer risk (pooled OR=1.10 (1.01–1.19) per 100 pmol/L increase in B12, P=0.002); the pooled OR for the association of folate with prostate cancer was positive (OR=1.11 (0.96–1.28) per 10 nmol/L, P=0.2) and conventionally statistically significant if ProtecT (the only case-control study) was excluded (OR=1.18 (1.00–1.40) per 10 nmol/L, P=0.02). Vitamin B12 and (in cohort studies) folate were associated with increased prostate cancer risk. Given current controversies over mandatory fortification, further research is needed to determine whether these are causal associations.